For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical fortunes, Brookfield Asset Management’s plan to take its troubled eponymous company private had been a way to turn it around — far from the glare of markets.

Brookfield Asset Management Ltd. is preparing to walk away from a plan to acquire Grifols SA over disagreements on valuation. The Spanish company’s billionaire founding family said it won’t support any new bid to take its namesake drug-maker private.

The Canadian fund Brookfield has decided to withdraw its interest in a public exclusion offer to acquire Grifols due to disagreements over the price with the

Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over the pharmaceutical company's value, while Grifols said it concurred with the decision.

Shares in Grifols were falling on Wednesday morning after Bloomberg reported Canadian fund Brookfield is considering dropping its plan to take over the Spanish pharmaceutical firm. The Canadian private equity firm is walking away on disagreement on the company's value,

Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following disagreement over its valuation.

Grifols (GRFS) stock dropped as Brookfield Asset Management (BAM) is reportedly withdrawing its offer to take the plasma therapeutics company private. Read more here.